secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001628280-25-025302
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics Q1 net loss narrows to $18.8M; pipeline advances with FHD-909 Phase 1 and degrader programs
--------------------------------------------------------------------------------

- Q1 2025 net loss $18.8M vs $25.0M in Q1 2024; collaboration revenue $6.0M (up from $5.1M).
- Cash, equivalents, and marketable securities $220.6M; cash runway into 2027.
- FHD-909 (SMARCA2 inhibitor) Phase 1 dose escalation in SMARCA4-mutated cancers ongoing, NSCLC primary target.
- Selective CBP degrader targeting IND in 2026; ARID1B and EP300 degrader program updates expected H2 2025.
- Board appointments: Neil Gallagher (Syndax President) and Stuart Duty (former Guggenheim Senior MD) in May 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025025302/0001628280-25-025302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025025302/fhtx-20250514.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-025302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer